BIAF
- bioAffinity Technologies, Inc.
()
Overview
Company Summary
BioAffinity Technologies, Inc. (BIAF) is a biotech company that specializes in the development and commercialization of innovative diagnostic tests for the early detection and monitoring of various types of cancers. The company focuses on leveraging the power of sophisticated technology and cutting-edge science to identify unique biomarkers that are indicative of specific cancer types.
BIAF's flagship product is called CyPath� Lung. This non-invasive diagnostic test utilizes flow cytometry and proprietary monoclonal antibodies to detect cancerous or precancerous changes in the cells present in a patient's sputum (mucus coughed up from the lungs). By analyzing specific cellular markers, CyPath� Lung can provide early detection and accurate diagnosis of lung cancer, potentially leading to timely and more effective treatment interventions.
The company also aims to expand its biomarker-based diagnostic platform to other types of cancer, including breast, colon, and prostate cancers. By identifying reliable and specific biomarkers for different cancers, BIAF's goal is to enhance diagnostic accuracy, enable personalized treatment plans, and improve patient outcomes.
In addition to its diagnostic tests, BIAF is involved in extensive research and development efforts to advance the field of cancer diagnostics. Their team of scientists and researchers are constantly working to identify, validate, and optimize new biomarkers that can be incorporated into their diagnostic platform.
Overall, bioAffinity Technologies, Inc. is dedicated to revolutionizing cancer diagnostics by providing early and accurate detection tools that can significantly impact patient outcomes and improve overall healthcare outcomes in the fight against cancer.